Research and Markets: Global Biosimilars: A return to optimism?

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/828136/global_biosimilars) has announced the addition of the "Global Biosimilars: A return to optimism?" report to their offering.

A Critical Strategic Analysis from Espicom

Despite some commentators predicting a muted or near nonexistent market for advanced biosimilars, many companies - and some surprising names - are positioning themselves for market entry.

The need for a settled market environment is essential if the growing numbers of biologic products losing patent protection in the next 5-10 years is to be exploited. However, progress is painfully slow.

Critical Issues Driving the market dynamic include:

• Industry investment: a sign of confidence?
• The US continues to disappoint; Europe forges ahead
• Developing markets may offer a profitable alternative

Recent Corporate Developments:

• Pfizer and Biocon announced a deal in October 2010 for the development and worldwide commercialisation of Biocon's recombinant insulin products.
• Boehringer Ingelheim announced the establishment of a separate biosimilar business in September 2011.
• Amgen and Watson announced a deal for the development of biosimilar versions of non-Amgen biologic products in December 2011.
• Baxter and Momenta Pharmaceuticals announced a joint-venture for the development of biosimilars in December 2011.
• Biogen Idec announced a joint-venture deal with the Korean conglomerate, Samsung, for the development of biosimilars. This will not include biosimilars of Biogen Idec products.
• Fujifilm have indicated they will create a joint-venture for the development of biosimilars in 2012.

PUBLICATION OVERVIEW

This report provides a comprehensive insight to the market environment, current and future products and the companies involved.

Key Features:

• A complete examination of the regulatory situation in the US, Europe and emerging markets
• Detailed assessment of current biosimilar products and developers with market share by product: EPO, G-CSF, HGH, Human Insulin, and Interferon (alfa & beta)
• Identification and analysis of likely second wave of advanced biologics to come to the market: Adalimumab, Etanercept, Infliximab, Rituximab, Trastuzumab
• A review of operational issues that will affect the adoption of biosimilars including pricing/reimbursement, clinician attitudes and patient acceptance
• The position, activity, products, pipeline and plans of 50 leading players in the field

For more information visit http://www.researchandmarkets.com/research/828136/global_biosimilars

Source: Espicom Business Intelligence Ltd